

Receptos Inc

CORTELLIS COMPANY DETAILED PIPELINE REPORT

A comprehensive coverage of the the company's drug pipeline portfolio including detailed product records.

Publication Date: 19-Jun-2013

THOMSON REUTERS

3 Times Square
New York, New York 10036
United States

Tel: +1 646 223 4000

thomsonreuters.com

[Return to Table of Contents](#)



ABOUT CORTELLIS COMPANY DETAILED PIPELINE REPORT

Thomson Reuters provides the knowledge, tools, and expertise to help support drug discovery and development activities, IP portfolio optimization, identification of licensing and partnering opportunities, delivery of successful regulatory submissions, and the ability to keep current with the rapidly-changing pharmaceutical and chemical markets, supporting informed, early decisions.

This report was created by Thomson Reuters, using information from *Thomson Reuters Cortellis™ for Competitive Intelligence*; a comprehensive, proven intelligence solution that leverages the most accurate, complete, and widely respected drug pipeline information. From drug discovery and development activities to patent reports, the latest deals, and partnering opportunities, *Cortellis* can provide the confidence to make the most informed business decisions, faster. *Cortellis for Competitive Intelligence* provides accurate and validated information on pharmaceutical and biotechnology companies globally, their drug pipelines, deals, patents, and clinical trials, plus breaking industry news and conference coverage. All contained in one simple, highly intuitive research platform.

Cortellis Company Detailed Pipeline reports are the second in a series of that track pharmaceutical and biotechnology companies worldwide. All *Cortellis for Competitive Intelligence* content is subject to the most comprehensive editorial review process available, conducted by scientists, pharma professionals, regulatory experts, and generics specialists. Featuring timely drug pipeline information expertly uncovered and integrated from over 400 global meetings each year, you'll always be on top of the latest developments.

Chosen by leading life sciences companies, their executives and investors, *Cortellis for Competitive Intelligence* accelerates your deal-making and gives you timely insights on the development landscape.

Discover undiscovered opportunities in drug development and licensing faster with *Thomson Reuters Cortellis™ for Competitive Intelligence*

DISCLAIMER

The information contained in this report is based on sources believed to be correct but Thomson Reuters does not guarantee the accuracy, timeliness, or completeness of this information. Opinions, if any, are those held by the author of any individual report or article at the time of initial publication and do not necessarily reflect the views of Thomson Reuters.

Information in this report on companies is intended for reference use only, and does not constitute a recommendation to buy or sell any particular security or other investment and does not constitute an offer to buy from or sell to any particular investor. Any company or securities mentioned in this report may not be suitable for any particular investor, depending on that investor's financial position and needs.

[Return to Table of Contents](#)



GLOSSARY

Number of Drugs in Active Development

Number of drugs associated with the company or subsidiary that are currently in active development, i.e. the development status for the drug(s) is one of the following: Discovery, Clinical, Phase I, Phase II, Phase III, Pre-registration, Registered, Launched, or Suspended.

Number of Inactive Drugs

Number of drugs associated with the company or subsidiary that are currently classified as inactive, i.e. where the development status for the drug(s) is one of the following: No Development Reported, Discontinued, or Withdrawn.

Number of Patents as Owner

Number of patents associated with the company where the company is listed as owner; i.e. the relationship type (or way the patent refers to the company) is: Patent Assignee/Owner, Patent owner (not assignee), Licensee for development and marketing, Licensee – marketing only (Distributor), Patent assignee of family member, Inferred assignee.

Number of Patents as Third Party

Number of patents associated with the company where the company is listed as third party; i.e. the relationship type (or way the patent refers to the company) is: Patent assignee (not owner), Ex-Licensee for development and marketing, Ex-Licensee marketing only (Distributor), Customer of technology, Ex-Customer of technology, Patent opponent or infringer, Affiliate organization of inventor, Owner of underlying technology.

Patents summary table

This table represents a summary of the core patent coverage for this company covering Therapeutic EP, US and WO patents since 1990 only.

Number of Deals

A count of deals where the company or one of its subsidiaries is the primary company.

Key Indications

Displays top ten key indications for the company and its subsidiaries based on frequency (indications occurring with high and identical frequency are always included, and this may result in more than ten Key Indications being listed). Includes both indications associated with patents where the company is patent owner and indications associated with drugs in active development. A drug is classified as 'active' if it features on a row (or rows) in the current development status table where the status is one of the following: Discovery, Clinical, Phase I, Phase II, Phase III, Pre-registration, Registered, Launched, or Suspended.

Key Target-based Actions

Displays top ten key target-based actions for the company and its subsidiaries based on frequency (actions occurring with high and identical frequency are always included, and this may result in more than ten Key Target-based Actions being listed). Includes both target-based actions associated with patents where the company patent owner and target-based actions associated with drugs in active development. A drug is classified as 'active' if it features on a row (or rows) in the current development status table where the status is one of the following: Discovery, Clinical, Phase I, Phase II, Phase III, Pre-registration, Registered, Launched, or Suspended. A target-based action is one that is associated with a target.

Key Technologies

Displays top ten key technologies for the company and its subsidiaries based on frequency (technologies occurring with high and identical frequency are always included, and this may result in more than ten Key Technologies being listed). Includes both key technologies associated with patents where the company relationship is patent owner and key technologies associated with drugs in active development. A drug is classified as 'active' if it features on a row (or rows) in the current development status table where the status is one of the following: Discovery, Clinical, Phase I, Phase II, Phase III, Pre-registration, Registered, Launched, or Suspended.

[Return to Table of Contents](#)



TABLE OF CONTENTS

Company Overview..... 5

Company Profile..... 6

Product Portfolio Summary..... 6

Product Portfolio Drug Pipeline Detail..... 10

 Phase 1 Clinical..... 11

 Discovery..... 15

[Return to Table of Contents](#)

Receptos Inc

COMPANY OVERVIEW

Company Name	Receptos Inc
Parent Company Name	Receptos Inc
Website	http://www.receptos.com/
Country	US
Number of Drugs in Active Development	3
Number of Inactive Drugs	1
Number of Patents as Owner	6
Number of Patents as Third Party	0
Number of Deals	5
Key Indications	Multiple sclerosis,Non-insulin dependent diabetes,Asthma,Eosinophilic esophagitis,Transplant rejection,Adult respiratory distress syndrome,Crohns disease,Influenza virus infection,Ulcerative colitis,Gestational diabetes,Insulin dependent diabetes,Metabolic disorder,Obesity
Key Target-based Actions	Glucagon-like peptide 1 agonist,Sphingosine-1-phosphate receptor-1 modulator,Sphingosine-1-phosphate receptor-1 agonist,IL-13 antagonist,Unspecified GPCR modulator
Key Technologies	Small molecule therapeutic,Oral formulation,Peptidomimetic,Analytical method,Antibody,Drug screening

COMPANY PROFILE

SUMMARY

Receptos was established in 2008 as Receptor Pharmaceuticals. By May 2009, it had changed its name to Receptos. Receptos focuses on the development of small molecule drugs targeting GPCRs.

ACQUISITIONS AND SPIN-OFFS

By November 2009, Receptos had acquired Apoptos.

LICENSING AGREEMENTS

By November 2009, Receptos had licensed GPCR structural biology technology and a patent estate from Scripps Research (Receptos' founders). Financial details were undisclosed.

FINANCIAL

In April 2013, the company filed a registration statement on Form S-1 with the US Securities and Exchange Commission for a proposed initial public offering of its common stock shares. In May 2013, Receptos priced the IPO of 5.2 million shares at \$14 per share. Underwriters were granted a 30-day overallotment option to purchase an additional 0.78 million shares. The offering was expected to close on May 14, 2013. Later that month, the IPO was closed. Receptos stock was listed on the NASDAQ Global Market under the symbol 'RCPT'.

In June 2011, the company expected series B financing in late 2011.

In November 2009, Receptos closed a two-tranche \$25 million series A financing.

[Return to Table of Contents](#)




PRODUCT PORTFOLIO SUMMARY

DRUGS

Drugs by Indication

Active Drugs by Indication Chart




[Return to Table of Contents](#)

Drugs by Indication Table

Indication	Active	Inactive	Total
Inflammatory disease	1	1	2
Respiratory disease	1	1	2
Immune disorder	2	0	2
Gastrointestinal disease	2	0	2
Metabolic disorder	1	0	1
Neurological disease	1	0	1
Endocrine disease	1	0	1

Drugs by Highest Status

Active Drugs by Highest Status Chart



Drugs by Highest Status Table

Development Status	Number of Drugs
Phase 1 Clinical	1
Discovery	2
No Development Reported	1

[Return to Table of Contents](#)

DEALS

Deal Type	Principal		Partner		Total
	Active	Inactive	Active	Inactive	
Technology - Other Proprietary	1	0	1	0	2
Drug - Early Research/Development	2	0	0	0	2
Drug - Development/Commercialization License	0	0	1	0	1

CLINICAL TRIALS

Trials by Condition Studied

Condition Studied	Ongoing	All
Immune disorder	0	2
Gastrointestinal disease	0	1
Neurological disease	0	1
Inflammatory disease	0	1

Trials by Phase

Phase	Ongoing	All
Phase 2	0	2
Phase 1	0	1
Phase not specified	0	1

Phase Definitions

Phase 3 Clinical

Includes Phase 3, Phase 3b, Phase 3a, Phase 2/3 (where enrolment count is 300 or over)

Phase 2 Clinical

Includes Phase 2, Phase 2a, Phase 2b, Phase 1/2 (where enrolment count is 100 or over), Phase 2/3 (where enrolment count is under 300 or not specified)

Phase 1 Clinical

Includes Phase 1, Phase 1a, Phase 1, Phase 1/2 (where enrolment count is under 100 or not specified), Phase 0

PATENTS *

Indication	As Owner	As Third Party	Total
Endocrine disease	2	0	2
Gastrointestinal disease	3	0	3
Immune disorder	3	0	3
Metabolic disorder	2	0	2

[Return to Table of Contents](#)



Neurological disease	2	0	2
Nutritional disorder	2	0	2
Respiratory disease	3	0	3
Infectious disease	1	0	1
Inflammatory disease	2	0	2

* This table represents a summary of the core patent coverage for this company covering Therapeutic EP, US and WO patents since 1990 only.

[Return to Table of Contents](#)

PRODUCT PORTFOLIO DRUG PIPELINE DETAIL

PLEASE NOTE: Highest status refers to highest development of that drug for one of the active companies

RPC-4046

RPC-4046 SNAPSHOT

Drug Name	RPC-4046
Key Synonyms	
Originator Company	Abbott Laboratories
Active Companies	Receptos Inc
Inactive Companies	AbbVie Inc;Abbott Laboratories
Highest Status	Phase 1 Clinical
Active Indications	Asthma;Eosinophilic esophagitis
Target-based Actions	IL-13 antagonist
Other Actions	Respiratory system agent;Anti-inflammatory
Technologies	Monoclonal antibody humanized;Subcutaneous formulation;Intravenous formulation;Biological therapeutic
Last Change Date	14-Mar-2013

RPC-4046 DEVELOPMENT PROFILE

SUMMARY

Receptos, under license from AbbVie (who presumably acquired the drug following its spin-out from Abbott in January 2013), is developing RPC-4046 (presumed to be ABT-308), a recombinant humanized monoclonal antibody against IL-13, for the potential iv or sc treatment of asthma and eosinophilic esophagitis,. In October 2009, AbbVie began a phase I trial; by April 2011, the trial had been completed. In March 2013, Receptos was planning a phase II proof-of-concept trial in the Orphan disease, eosinophilic esophagitis.

RPC-4046 DEVELOPMENT STATUS

CURRENT DEVELOPMENT STATUS

Company	Indication	Country	Development Status	Date
Receptos Inc	Asthma	US	Phase 1 Clinical	13-Mar-2013
Receptos Inc	Eosinophilic esophagitis	US	Discovery	13-Mar-2013
AbbVie Inc	Asthma	US	Discontinued	13-Mar-2013
Abbott Laboratories	Asthma	US	Discontinued	02-Jan-2013

[Return to Table of Contents](#)



RPC-4046 DRUG NAMES

Names	Type
anti-asthmatic agent, Abbott	
RPC-4046	Research Code
anti-IL-13 mAb (eosinophilic esophagitis), Receptos	
ABT-308	Research Code

RPC-4046 CLINICAL TRIALS


Total Trials by Phase and Status

Phase 4 Clinical		Phase 3 Clinical		Phase 2 Clinical		Phase 1 Clinical		Phase Unspecified		Total	
On-going	All	On-going	All	On-going	All	On-going	All	On-going	All	On-going	All
Total by Phase and Status											
0	0	0	0	0	0	0	1	0	0	0	1

RPC-4046 DEALS AND PATENTS

DEALS

Deals by Parent Company Chart




[Return to Table of Contents](#)

Deals by Parent Company Table

Company Name	Principal		Partner		Total
	Active	Inactive	Active	Inactive	
Receptos Inc	0	0	1	0	1
AbbVie Inc	1	0	0	0	1

Deals by Type Chart




Deals by Type Table

Deal Type	Active	Inactive	Total
Drug - Development/Commercialization License	1	0	1

[Return to Table of Contents](#)

PATENTS

Patents by Parent Company Chart




Patents by Parent Company Table

Company Name	As Owner	As Third Party	Total
Abbott Laboratories	2	0	2
AbbVie Inc	2	0	2
Receptos Inc	1	0	1
Abbott Research Group Inc	1	0	1

[Return to Table of Contents](#)

Patents by Drug Relationship Type Chart



Patents by Drug Relationship Type Table

Drug Relationship	Total
Product	1
Formulation	1
Process	1

RPC-1063 metabolites (Multiple sclerosis) Receptos, Inc.,

RPC-1063 metabolites (Multiple sclerosis) Receptos, Inc., SNAPSHOT

Drug Name	RPC-1063 metabolites (Multiple sclerosis) Receptos, Inc.,
Key Synonyms	
Originator Company	Receptos Inc
Active Companies	Receptos Inc
Inactive Companies	
Highest Status	Discovery
Active Indications	Multiple sclerosis
Target-based Actions	Sphingosine-1-phosphate receptor-1 modulator
Other Actions	
Technologies	Small molecule therapeutic
Last Change Date	30-Mar-2013

RPC-1063 metabolites (Multiple sclerosis) Receptos, Inc., DEVELOPMENT PROFILE

SUMMARY

Receptos Inc is investigating the metabolites of RPC-1063, including RP-101988, RP-101075 and RP-101442, which are selective sphingosine-1 phosphate-1 receptor (S1P1R) modulators, for the potential treatment of multiple sclerosis. In March 2013, preclinical data were presented.

RPC-1063 metabolites (Multiple sclerosis) Receptos, Inc., DEVELOPMENT STATUS

CURRENT DEVELOPMENT STATUS

Company	Indication	Country	Development Status	Date
Receptos Inc	Multiple sclerosis	US	Discovery	29-Mar-2013

RPC-1063 metabolites (Multiple sclerosis) Receptos, Inc., DRUG NAMES

Names	Type
RP-101075	Metabolite
RP-101442	Metabolite
RP-101988	Metabolite
RPC-1063 metabolites (Multiple sclerosis) Receptos, Inc.,	

[Return to Table of Contents](#)





GLP1 positive allosteric modulators (oral, type 2 diabetes), Receptos

GLP1 positive allosteric modulators (oral, type 2 diabetes), Receptos SNAPSHOT

Drug Name	GLP1 positive allosteric modulators (oral, type 2 diabetes), Receptos
Key Synonyms	
Originator Company	Receptos Inc
Active Companies	Receptos Inc
Inactive Companies	
Highest Status	Discovery
Active Indications	Non-insulin dependent diabetes
Target-based Actions	Glucagon-like peptide 1 agonist
Other Actions	Hypoglycemic agent
Technologies	Oral formulation;Peptidomimetic;Small molecule therapeutic
Last Change Date	21-Nov-2012

GLP1 positive allosteric modulators (oral, type 2 diabetes), Receptos DEVELOPMENT PROFILE

SUMMARY

Receptos is investigating a program of small molecule glucagon-like peptide 1 receptor (GLP1R) positive allosteric modulators, for the potential oral treatment of type 2 diabetes,. In October 2011, preclinical development had begun ; research was ongoing in June 2012 . In October 2011, the company's strategy involved seeking to outlicense its programs.

GLP1 positive allosteric modulators (oral, type 2 diabetes), Receptos DEVELOPMENT STATUS

CURRENT DEVELOPMENT STATUS

Company	Indication	Country	Development Status	Date
Receptos Inc	Non-insulin dependent diabetes	US	Discovery	31-Dec-2009

GLP1 positive allosteric modulators (oral, type 2 diabetes), Receptos DRUG NAMES

Names	Type
GLP1 positive allosteric modulators (oral, type 2 diabetes), Receptos	
GLP1R agonists, Receptos	
GLP1R agonists (oral, type 2 diabetes), Receptos	

[Return to Table of Contents](#)



This report was created by Thomson Reuters, using information from *Thomson Reuters Cortellis™ for Competitive Intelligence*; a comprehensive, proven intelligence solution that leverages the most accurate, complete, and widely respected drug pipeline information.

For more information about *Cortellis for Competitive Intelligence*, visit:

http://cortellis.thomsonreuters.com/cortellis_for_you/?cid=thomsonone.

For subscription information, e-mail scientific.lifesciences@thomsonreuters.com.

© 2012 Thomson Reuters. All rights reserved.
Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks and trademarks of Thomson Reuters and its affiliated companies.

[Return to Table of Contents](#)

